Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia.
about
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disordersThe therapeutic potential of cannabis and cannabinoidsMedical marijuana: clearing away the smokeCannabinoids in health and diseaseTreating nausea and vomiting in palliative care: a reviewThe endocannabinoid system as an emerging target of pharmacotherapyClinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDSPathophysiology of anorexia in the cancer cachexia syndromeThe assessment of complementary and alternative medicine use among individuals with HIV: a systematic review and recommendations for future researchMarijuana Legalization: Impact on Physicians and Public HealthFood for thought: endocannabinoid modulation of lipogenesis.Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter SurveyDiscovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors.Chronic Δ⁹-tetrahydrocannabinol administration may not attenuate simian immunodeficiency virus disease progression in female rhesus macaques.Evaluation of [11C]PipISB and [18F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type-1 receptors in vivo.The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia.Tolerance to chronic delta-9-tetrahydrocannabinol (Δ⁹-THC) in rhesus macaques infected with simian immunodeficiency virusEfficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory studyThe safety of cannabinoids for the treatment of multiple sclerosis.Guidelines for the use of orexigenic drugs in long-term care.How many sites of action for endocannabinoids to control energy metabolism?Evaluation and management of patients with pulmonary nontuberculous mycobacterial infections.Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected Patients.Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.Weight loss treatment in long-term care:are outcomes improved with oral supplements and appetite stimulants?.Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers.Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers.Update on emerging drugs for cancer cachexia.Examining the roles of cannabinoids in pain and other therapeutic indications: a review.Medical marijuana: A panacea or scourge.Medical marijuana for digestive disorders: high time to prescribe?Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….Medical uses of marijuana (Cannabis sativa): fact or fallacy?Symptom burden in heart failure: assessment, impact on outcomes, and management.[Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety].The Use of Cannabinoids in Treating Dementia.Endocannabinoids in arthritis: current views and perspective.Association between cerebral cannabinoid 1 receptor availability and body mass index in patients with food intake disorders and healthy subjects: a [(18)F]MK-9470 PET study.Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study.
P2860
Q22299116-47FDCF1F-7C15-4E24-B465-F98E35D11B90Q24600806-6A78DE6E-5682-4B64-B1F3-B97117A18B0CQ24617731-E98F8772-33A4-48D1-89F0-4513636A6CD0Q24633884-31A5CA19-F120-477D-8A41-D199B941DA98Q24635649-69831E9F-B0DE-4E88-B395-E1A67EC4B2BBQ24648473-2C8D845D-EE5D-4FA0-AC86-69B19804FB87Q26765257-9B069684-BE1C-4F87-AFDC-A24F19A380E0Q26775294-3017D346-D802-4203-BC5F-F9C3FD1308DCQ27022858-93F30CEF-0054-4B07-B73F-0CBAAD303F30Q28082785-AD41B17D-8F8A-4CFF-83B7-692F83391F65Q33768340-C026587B-9DF5-4E92-AB9E-8BFFAEABFF01Q34077887-A66EA3AC-632F-4EB7-8D83-1B69A274112EQ34278963-FD59C1E6-D04A-4CDA-AA47-5F59C0262F16Q34606565-6B2F2E17-1906-495B-86D1-70F90DA632F5Q34858094-07657172-C4B1-45CB-AC7F-819EFD616955Q34988386-3700CD43-E2E9-4B92-8A72-D4992AEED3F2Q35119113-DB45F7BC-793B-47CC-864D-9753DC9A89FAQ35887456-E33242B9-8030-4513-88EF-C69C858D5AEAQ36150541-1C57E9CC-316A-4615-AC43-1EA838595C23Q36378763-8E695A48-DCE9-4D1F-8B31-FFBEFC0FAE15Q36434447-8A7E531E-B6F9-4AB7-B4E8-46B21E7C9090Q36688950-CFD897C1-CDD0-4882-A579-AF996B404EEEQ36835326-731B8630-3D11-4E5D-90DC-AD6FFF42B664Q36892931-2046AB29-976C-49F6-B7B1-69B2C7A0D727Q36941905-5203C1AE-3678-4032-ADA6-8E67593A242EQ37088702-7CBBFEFC-ABBE-4F5D-A205-0B502D01C649Q37344285-536A38E5-6C32-482F-83A5-8C084ADDB3E5Q37588109-8EEAA3F4-E96F-4468-B20F-2227D9CEC1ABQ37622253-5E5D4744-89B3-4B67-BE87-83026BFB92B7Q37650292-5C5E7337-305F-4FB3-9688-CEE9FB008B6AQ37723348-347F5FFA-E095-4E7B-ADB1-663FCB007B65Q38246940-3CC83ABB-C7F3-4301-8E0B-E88F75B79D17Q38503842-275B4829-6F0E-4719-88B1-81247C666464Q38540829-3C22E32A-E0AD-4433-A61B-FA59C3667384Q38945834-DEC6FF96-8818-4F3D-A50F-D19B8C7A38B7Q39177603-17C2B6B7-00D6-4296-A921-6134C7837237Q39385097-35AE2C84-05CE-4439-A267-B5B4B977BE0DQ39453798-2A142E0D-2BF1-42A3-85B0-9EFC171109D5Q41271075-EC49CC00-9342-467A-B94A-C8E812AB18B2Q42601467-545A091F-6F6A-428A-BCF6-57CC538697EB
P2860
Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Long-term efficacy and safety ...... syndrome-associated anorexia.
@ast
Long-term efficacy and safety ...... syndrome-associated anorexia.
@en
Long-term efficacy and safety ...... syndrome-associated anorexia.
@nl
type
label
Long-term efficacy and safety ...... syndrome-associated anorexia.
@ast
Long-term efficacy and safety ...... syndrome-associated anorexia.
@en
Long-term efficacy and safety ...... syndrome-associated anorexia.
@nl
prefLabel
Long-term efficacy and safety ...... syndrome-associated anorexia.
@ast
Long-term efficacy and safety ...... syndrome-associated anorexia.
@en
Long-term efficacy and safety ...... syndrome-associated anorexia.
@nl
P2093
P1476
Long-term efficacy and safety ...... syndrome-associated anorexia.
@en
P2093
Laubenstein L
Lefkowitz L
Morales JO
Mosdell KW
Powderly W
P356
10.1016/S0885-3924(97)00038-9
P577
1997-07-01T00:00:00Z